← All Igc Pharma, INC filings

Igc Pharma, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX
IGC
Igc Pharma, INC
10-K: IGC Pharma Narrows Focus to Life Sciences, Reports Reduced Losses and Positive Alzheimer's Drug Trial Data
IGC Pharma, Inc. has strategically realigned its operations to focus solely on Life Sciences, reporting a significant reduction in net losses and encouraging interim Phase 2 clinical trial results for its lead Alzheimer's drug candidate, IGC-AD1, despite a decrease in overall revenue and cash reserves.
AMEX
IGC
Igc Pharma, INC
10-K: IGC Pharma Reports Promising Phase 2 Trial Results for Alzheimer's Agitation Treatment
IGC Pharma's lead drug, IGC-AD1, shows significant reduction in agitation for Alzheimer's patients in a Phase 2 trial, with a faster onset of action compared to traditional medications.